Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Liquid Biopsy Markets by Cancer Type, by Diagnosis, Monitoring & Recurrence Testing 2019-2023 - Historical Data Including Screening Market Potential Size with Executive and Consultant Guides -

Research and Markets
Posted on: 23 Mar 18

The "Liquid Biopsy Markets by Cancer Type, by Diagnosis, Monitoring & Recurrence Testing 2019-2023 - Historical Data Including Screening Market Potential Size with Executive and Consultant Guides" report has been added to's offering.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures.

The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2023. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.

Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers as well as breakouts by Diagnostic, Therapy Monitoring and Recurrence Monitoring.

What is the size of the huge screening opportunity? They are all listed in Chapter 10.

Key Topics Covered:

1. Introduction and Market Definition

1.1 What is Liquid Biopsy?

1.2 The Sequencing Revolution

1.3 Market Definition

1.4 Methodology

2. Market Overview

2.1 Players in a Dynamic Market

2.2 Using Biopsies

2.3 Biopsy Sites

2.4 The Situation Today - Biopsy Analysis

2.5 Evidence of Cancer - Liquid Biopsy Technology

2.6 Cancer Treatment Protocol Under Siege

2.7 Structure of Industry Plays a Part

2.8 Profiles of Key Players

3. Market Trends

3.1 Factors Driving Growth

3.2 Factors Limiting Growth

3.3 Instrumentation and Automation

3.4 Diagnostic Technology Development

4. Liquid Biopsy Recent Developments

4.1 Recent Developments - Importance and How to Use This Section

4.1.1 Importance of These Developments

4.1.2 How to Use This Section

4.2 Avalon GloboCare, Da An Gene Collaborate on Liquid Biopsy Diagnostics

4.3 OncoDNA Inks Russian Distribution Deal With Genext

4.4 Biocept Prices $15M Public Offering

4.5 UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests

4.6 Exact Sciences Shares Drop on Threat From Liquid Biopsy

4.7 Personal Genome Diagnostics Nets $75M in Series B Financing

4.8 Circulogene Licenses Liquid Biopsy Tech to Turkish Lab

4.9 Genomic Health, Cleveland Diagnostics Ink Deal to Commercialize Prostate Cancer Tests

4.10 Biocartis Gets CE Marking for Two Colorectal Cancer Liquid Biopsy Tests

4.11 OncoCyte Q3 Net Loss Swells, Lung Cancer Dx Launch Delayed

4.12 Natera, Aarhus University Collaborate on Liquid Biopsy Study for Colorectal Cancer

4.13 MDxHealth Nine-Month Revenues Up 38 Percent

4.14 Clinical Genomics, MSKCC to Study Rectal Cancer Liquid Biopsy Monitoring

4.15 Collaboration in Japan Using Exosomes for Better Cancer Diagnoses, Treatment

4.16 Cancer MDx Firm Bioarray Genetics Raises $4M

4.17 Biocept Inks US Marketing Deal for Target Selector Liquid Biopsy Tech

4.18 Exosome Diagnostics Launches Evidence Development Study for Prostate Cancer Test

4.19 Angle to Buy Axela, Plans to Raise 12.2M in Share Placement

4.20 Mutation Count in ctDNA Predicts Patient Response to Immunotherapy

4.21 Qiagen, Angle to Comarket Liquid Biopsy Technologies

4.22 Cancer MDx Firm Bioarray Genetics Raises $4M

4.23 Genentech Adapts Microfluidics Sequencing Method for Liquid Biopsy Applications

4.24 OncoDNA Gains UK Reimbursement for OncoStrat&Go

4.25 Sequencing of Circulating Tumor DNA Detects Early Cancers

4.26 RareCyte announces $30M round

4.27 Liquid Biopsies May Never Replace Tissue Biopsies

4.28 Karius reels in $50M to ramp up infectious disease liquid biopsy

4.29 Liquid Biopsy Passes Test for Nasopharyngeal Cancer

4.30 Exosome Diagnostics Launches the MedOncAlyzer Pan-Cancer Panel

4.31 Lonza Acquires HansaBioMed, Invests in Exosomics

4.32 Controversial Test Highlights Precision Medicine Marketing, Regulatory Issues

4.33 Trovagene Announces Agreement with Global Biopharmaceutical Company

4.34 Liquid Biopsy Firms Move Toward Multianalyte Detection

4.35 In a first, China approves Amoy's lung cancer liquid biopsy

5. Country Market Sizes - North America

5.1 United States of America

5.2 Canada

6. Country Markets - Europe

7. Country Markets - Asia Pacific

8. Country Markets - Latin America, Africa & The Middle East

9. Global Market Summary

10. Potential Market Opportunity Sizes

10.1 Cancer Screening by Country: Lung, Breast & Colorectal

10.2 Cancer Screening by Country: Prostate, Other Cancer & All Cancer

10.3 Potential Market Size - Cancer Diagnosis

10.4 Potential Market Size - Cancer Management


I. United States Medicare System: January 2018 Clinical Laboratory Fees Schedule - National Limit and Midpoint

II. FDA Approved Human Genetic Tests

III. FDA Approved Pharmacogenomics Tests

For more information about this report visit

View source version on

Business Wire

Last updated on: 23/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.